Clinic Roundup
The Belgian Federal Agency for Medicines and Health Products gave authorization to Cardio3 BioSciences, of Mont-Saint-Guibert, Belgium, to begin a Phase III trial of C3BS-CQR-1, an autologous stem cell therapy, for congestive heart failure.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.